Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Told you so

<< Previous

Bullboard Posts

Next >>

Comment by skiboard09on Sep 11, 2021 11:43am

159 Views

Post# 33844989

RE:RE:RE:RE:Told you so

The higher concentration 1067 is just ONE thing we should be hearing about.

don't forget the list of other milestones we are still way past overdue on. Why can't they keep to a timeline they published.. what is Howard doing? I feel like a new CEO announcement and we would double in value. People are tired of not hitting the timelines they give to shareholders. It's the same old story. Hype up milestones followed by zero execution or massive delays

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec